Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience

The purpose of the present study was to understand the effect of early relapse (ER) on the overall survival of myeloma patients. We analyzed the outcomes of 257 patients who had received novel agent-based induction therapy and undergone single autologous stem cell therapy at our center from 2010 to 2016. We have concluded that ER, high-risk cytogenetics, and lactate dehydrogenase> 350 UI/L are significant prognosticators for poor patient outcome in those with multiple myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Intensive first-line treatment for mantle cell lymphoma (MCL), incorporating rituximab and cytarabine followed by autologous stem cell transplantation (ASCT) consolidation for responding patients, affords high response rates and a progression-free survival exceeding 5 years. 1-3 Nonetheless, MCL remains incurable, and high-risk subsets defined by the Mantle Cell International Prognostic Index (MIPI4, 5) do not achieve the same benefit from intensified therapies.2, 6, 7 The Nordic regimen employing intensified rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (maxi-RCHOP) alternating with rituximab and c...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractDuring the past decade, the survival outcomes of patients with multiple myeloma (MM) have dramatically improved, not only owing to the advent of a number of novel therapies, but also to the deepening insight regarding how to best use these options. Triplet-based induction regimens can yield overall response rates of ≤ 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options available with high and durable response rates. The addi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractOver the last decade the survival outcomes in Multiple Myeloma (MM) have dramatically improved thanks to not only the advent of a number of novel therapies; but also, to the deepening insight regarding how to best utilize these options. Triplet-based induction regimens can yield overall response rates of up to 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options with high and durable response rates. The addition of monoclonal antibod...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsAllogeneic SCT results extend survival in selected patients with relapsed/refractory HL, showing low treatment-related mortality. Patients with active disease at the time of allogeneic transplantation have poor outcomes. Allogeneic SCT may be an effective salvage strategy for patients who relapse after an autologous SCT.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsrAML remains a clinical challenge. Genetic variability in outcomes was observed. A majority of patients with inv(16) were successfully salvaged post relapse while patients with 11q23 rearrangement had a poor prognosis. Only a third of those with t(8;21) rAML survived. Better access to SCT in HIDC is needed.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionMesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study reports a retrospective multicentre experience of the Rete Ematologica Pugliese (REP) over the past 17 years, aiming to define the impact of each patient’s disease and transplant-related characteristics on outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusions: This is the largest single centre data on outcomes of various haematological malignancies from India. This real world data identifies areas which need further attention to improve outcomes.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsOur study revealed aberrant genetic aberrations in signaling networks that may contribute to race-specific aspects of leukemogenesis. Our results suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children afflicted by B-ALL. These findings may ultimately impact disease management and contribute to the elimination of disparate outcomes in AA children with B-ALL.Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xianrui Zhang, Meiyun FangAbstractTEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential b...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study